Advertisement

Neoplasia and Mononuclear Phagocyte Function

  • George J. Cianciolo
  • Ralph Snyderman

Abstract

While the concept of immune surveillance has come under attack during the last decade (Prehn and Lappe, 1971; Prehn, 1972; Stutman, 1975; Prehn, 1976; Möller and Möller, 1976, 1978), there is substantial evidence that macrophages may play an important role in host defense against neoplasia (Alexander, 1976; Hopper and Pimm, 1976; Adams and Snyderman, 1979; Nathan et al., 1980). Macrophages are capable of infiltrating tumors and killing tumor cells in vitro and in vivo. Moreover, suppression of macrophage function can enhance tumor growth. Interestingly, there is substantial evidence that virulent tumors can enhance their ability to escape immunologically mediated destruction by releasing factors that affect mononuclear phagocyte function. At least some of the factors associated with tumors that alter macrophage function appear to be antigenically related to viral structural proteins.

Keywords

Peritoneal Macrophage Chemotactic Activity Macrophage Function Macrophage Accumulation Lewis Lung Carcinoma Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adams, D. O., and Snyderman, R., 1979, Do macrophages destroy nascent tumors?, J. Natl. Cancer Inst. 62:1341.PubMedGoogle Scholar
  2. Alexander, P., 1976, Surveillance against neoplastic cells—Is it mediated by macrophages?, Br. J. Cancer 33:344.PubMedCrossRefGoogle Scholar
  3. Baum, M., and Fisher, B., 1972, Macrophage production by the bone marrow of tumor-bearing mice, Cancer Res. 32:2813.PubMedGoogle Scholar
  4. Berenberg, J. L., and Ward, P. A., 1973, Chemotactic factor inactivator in normal human serum, J. Clin. Invest. 52:1200.PubMedCrossRefGoogle Scholar
  5. Berg, J. W., 1959, Inflammation and prognosis in breast cancer, Cancer 12:714.PubMedCrossRefGoogle Scholar
  6. Bernstein, I. D., Zbar, B., and Rapp, H. J., 1972, Impaired inflammatory response in tumor-bearing guinea pigs, J. Natl. Cancer Inst. 49:1641.PubMedGoogle Scholar
  7. Boetcher, D. A., and Leonard, E. J., 1974, Abnormal monocyte chemotactic response in cancer patients, J. Natl. Cancer Inst. 52:1091.PubMedGoogle Scholar
  8. Brozna, J. P., and Ward, P. A., 1975, Antileukotactic properties of tumor cells, J. Clin. Invest. 56:616.PubMedCrossRefGoogle Scholar
  9. Carr, I., Price, P., and Westby, S., 1976, The effects of tumor extract on macrophage proliferation in lymph nodes, J. Pathol. 120:251.PubMedCrossRefGoogle Scholar
  10. Cheung, H. T., Cantarow, W. D., and Sundharadas, G., 1979, Characteristics of a low-molecular-weight factor extracted from mouse tumors that affects in vitro properties of macrophages, Int. J. Cancer 23:344.PubMedCrossRefGoogle Scholar
  11. Cianciolo, G. J., and Snyderman, R., 1981, Monocyte responsiveness to chemotactic stimuli is a property of a subpopulation of cells which can respond to multiple chemoattractants, J. Clin. Invest. 67:60.PubMedCrossRefGoogle Scholar
  12. Cianciolo, G. J., Herberman, R. B., and Snyderman, R., 1980a, Depression of murine macrophage accumulation by low-molecular-weight factors derived from spontaneous mammary carcinomas, J. Natl. Cancer Inst. 65:829.PubMedGoogle Scholar
  13. Cianciolo, G. J., Matthews, T. J., Bolognesi, D. P., and Snyderman, R., 1980b, Macrophage accumulation in mice is inhibited by low molecular weight products from murine leukemia viruses, J. Immunol. 124:2900.PubMedGoogle Scholar
  14. Cianciolo, G., Hunter, J., Silva, J., Haskill, J. S., and Snyderman, R., 1981, Inhibitors of monocyte responses to chemotaxins are present in human cancerous effusions and react with monoclonal antibodies to the P15(E) structural protein of retroviruses, J. Clin. Invest. 68:831.PubMedCrossRefGoogle Scholar
  15. Dizon, Q. S., and Southam, C. M., 1963, Abnormal cellular response to skin abrasion in cancer patients, Cancer 16:1288.PubMedCrossRefGoogle Scholar
  16. Eccles, S. A., and Alexander, P., 1974a, Macrophage content of tumors in relation to metastatic spread and host immune reaction, Nature (London) 250:667.CrossRefGoogle Scholar
  17. Eccles, S. A., and Alexander, P., 1974b, Sequestration of macrophages in growing tumors and its effect on the immunological capacity of the host, Br. J. Cancer 30:42.PubMedCrossRefGoogle Scholar
  18. Eccles, S. A., Bandlow, G., and Alexander, P., 1976, Monocytosis associated with the growth of transplanted syngeneic rat sarcomata differing in immunogenicity, Br. J. Cancer 34:20.PubMedCrossRefGoogle Scholar
  19. Evans, R., 1972, Macrophages in syngeneic animal tumors, Transplantation 14:468.PubMedCrossRefGoogle Scholar
  20. Fauve, R. M., Hevin, B., Jacob, H., Gaillard, J. A., and Jacob, F., 1974, Antiinflammatory effects of murine malignant cells, Proc. Natl. Acad. Sci. USA 71:4052.PubMedCrossRefGoogle Scholar
  21. Gauci, C. L., and Alexander, P., 1975, The macrophage content of some human tumors, Cancer Lett. 1:29.PubMedCrossRefGoogle Scholar
  22. Gauci, C. L., Wrathmell, A., and Alexander, P., 1975, The origin and role of blood-bone monocytes in rats with a transplanted myelogenous leukemia, Cancer Lett. 1:33.PubMedCrossRefGoogle Scholar
  23. Ghaffar, A., McBride, W. H., and Cullen, R. T., 1976, Interaction of tumor cells and activated macrophages in vitro: Modulation by Corynebacterium parvum and gold salts, J. Reticuloendothelial Soc. 20:283.Google Scholar
  24. Goldsmith, H. S., Levin, A. G., and Southam, C.M., 1965, A study of cellular responses in cancer patients by qualitative and quantitative Rebuck tests, Surg. Forum 16:102.PubMedGoogle Scholar
  25. Hakim, A. A., 1980, Lipid-like agent from human neoplastic cells suppresses cell-mediated immunity, Cancer Immunol. Immunother. 8:133.CrossRefGoogle Scholar
  26. Haskill, J. S., Proctor, J. W., and Yamamura, Y., 1975, Host responses within solid tumors. I. Monocytic effector cells within rat sarcomas, J. Natl. Cancer Inst. 54:387.PubMedGoogle Scholar
  27. Hausman, M., Brosman, S., Fahey, J. L., and Snyderman, R., 1973, Defective mononuclear leukocyte chemotactic activity in patients with genitourinary carcinoma, Clin. Res. 21:646A.Google Scholar
  28. Hausman, M. S., Brosman, S., Snyderman, R., Mickey, M. R., and Fahey, J., 1975, Defective monocyte function in patients with genitourinary carcimona, J. Natl. Cancer Inst. 55:1047.PubMedGoogle Scholar
  29. Hopper, D. G., and Pimm, M. V., 1976, Macrophages v. cancer, Lancet 2:255.Google Scholar
  30. Johnson, M. W., Maibach, H. I., and Salmon, S. E., 1971, Skin reactivity in patients with cancer, N. Engl. J. Med. 284:1255.PubMedCrossRefGoogle Scholar
  31. Johnson, M. W., Maibach, H. I., and Salmon, S. E., 1973, Quantitative impairment of primary inflammatory response in patients with cancer, J. Natl. Cancer Inst. 51:1075.PubMedGoogle Scholar
  32. Keller, R., 1976, Promotion of tumor growth in vivo by antimacrophage agents, J. Natl. Cancer Inst. 57:1355.PubMedGoogle Scholar
  33. Keller, R., 1977, Abrogation of antitumor effects of Corynebacterium parvum and BCG by anti-macrophage agents, J. Natl. Cancer Inst. 59:1751.PubMedGoogle Scholar
  34. Kjeldsberg, C. R., and Pay, G. D., 1978, A qualitative and quantitative study of monocytes in patients with malignant solid tumors, Cancer 41:2236.PubMedCrossRefGoogle Scholar
  35. McBride, W. H., Tuach, W., and Marmion, B. P., 1975, The effects of gold salts on tumor immunity and its stimulation by Corynebacterium parvum, Br. J. Cancer 32:558.PubMedCrossRefGoogle Scholar
  36. Mahoney, M. J., and Leighton, J., 1961, The inflammatory response to a foreign body within transplantable tumors, Cancer Res. 22:334.Google Scholar
  37. Meltzer, M. S., and Stevenson, M. M., 1978, Macrophage function in tumor-bearing mice: Dissociation of phagocytic and chemotactic responsiveness, Cell. Immunol. 35:99.PubMedCrossRefGoogle Scholar
  38. Meltzer, M. S., Stevenson, M. M., and Leonard, E. J., 1977, Characterization of macrophage chemo-taxis in tumor cell cultures and comparison with lymphocyte-derived chemotactic factors, Cancer Res. 37:721.PubMedGoogle Scholar
  39. Möller, G., and Möller, E., 1976, The concept of immunological surveillance against neoplasia, Transplant. Rev. 28:3.PubMedGoogle Scholar
  40. Möller, G., and Möller, E., 1978, Immunological surveillance against neoplasia, in: Immunological Aspects of Cancer (J. E. Castro, ed.), pp. 205–217, University Park Press, Baltimore.Google Scholar
  41. Nathan, C. F., Murray, H. W., and Cohn, Z. A., 1980, The macrophage as an effector cell, N. Engl. J. Med. 303:622PubMedCrossRefGoogle Scholar
  42. Nelson, D. S., and Kearney, R., 1976, Macrophages and lymphoid tissues in mice with concomitant tumor immunity, Br. J. Cancer 34:221.PubMedCrossRefGoogle Scholar
  43. Nelson, M., and Nelson, D. S., 1978, Macrophages and resistance to tumors. I. Inhibition of delayed-type hypersensitivity reactions by tumor cells and by soluble products affecting macrophages, Immunology 34:277.PubMedGoogle Scholar
  44. Normann, S. J., and Sorkin, E., 1976, Cell specific defect in monocyte function during tumor growth, J. Natl. Cancer Inst. 57:135.Google Scholar
  45. Normann, S. J., and Sorkin, E., 1977, Inhibition of macrophage chemotaxis by neoplastic and other rapidly proliferating cells in vitro, Cancer Res. 37:705.PubMedGoogle Scholar
  46. Normann, S. J., Schardt, M., and Sorkin, E., 1979, Antiinflammatory effect of spontaneous lymphoma in SJLJJ mice, J. Natl. Cancer Inst. 63:825.PubMedGoogle Scholar
  47. Otu, A. A., Russell, R. J., Wilkinson, P. C., and White, R. G., 1977, Alterations of mononuclear phagocyte function induced by Lewis lung carcinoma in C57BL mice, Br. J. Cancer 36:330.PubMedCrossRefGoogle Scholar
  48. Prehn, R. T., 1972, The immune reaction as a stimulator of tumor growth, Science 175:170.CrossRefGoogle Scholar
  49. Prehn, R. T., 1976, Do tumors grow because of the immune response of the host?, Transplant. Rev. 28:34.PubMedGoogle Scholar
  50. Prehn, R. T., and Lappe, M. A., 1971, An immunostimulation theory of tumor development, Transplant. Rev. 7:26.PubMedGoogle Scholar
  51. Rubin, R. H., Cosimi, A. B., and Goetzl, E. J., 1976, Defective human mononuclear leukocyte chemotaxis as an index of host resistance to malignant melanoma, Clin. Immunol. Immunpathol. 6:376.CrossRefGoogle Scholar
  52. Russell, S. W., Doe, W. F., and Cochrane, C. G., 1976, Number of macrophages and distribution of mitotic activity in regressing and progressing Moloney sarcomas, J. Immunol. 116:164.Google Scholar
  53. Russell, S. W., Doe, W. F., and Mclntosh, A. T., 1977, Functional characterization of a stable, non-cytolytic stage of macrophage activation in tumors, J. Exp. Med. 146:1511.PubMedCrossRefGoogle Scholar
  54. Simon, L. S., Patterson, R., and Jones, T. L., 1980, A rapid method for assessment of a macrophage chemoattractant produced by SaD2 fibrosarcoma cells in vitro, J. Immunol. Methods 32:195.PubMedCrossRefGoogle Scholar
  55. Snodgrass, M. J., Harris, T. M., and Kaplan, A. M., 1978, Chemokinetic response of activated macrophages to soluble products of neoplastic cells, Cancer Res. 38:2925.PubMedGoogle Scholar
  56. Snyderman, R., and Cianciolo, G. J., 1979, Further studies of a macrophage chemotaxis inhibitor (MCI) produced by neoplasms: Murine tumors free of lactic dehydrogenase virus produce MCI, J. Reticuloendothelial Soc. 26:453.Google Scholar
  57. Snyderman, R., and Pike, M. C, 1976a, Defective macrophage migration produced by neoplasms: Identification of an inhibitor of macrophage chemotaxis, in: The Macrophage in Neoplasia (M. A. Fink, ed.), Academic Press, New York.Google Scholar
  58. Snyderman, R., and Pike, M. C., 1976b, An inhibitor of macrophage chemotaxis produced by neoplasms, Science 192:370.PubMedCrossRefGoogle Scholar
  59. Snyderman, R., Altman, L. C., Hausman, M. S., and Mergenhagen, S. E., 1972, Human mono-nuclear leukocyte chemotaxis: A quantitative assay for humoral and cellular factors, J. Immunol. 108:857.PubMedGoogle Scholar
  60. Snyderman, R., Dickson, J., Meadows, L., and Pike, M., 1974, Deficient monocyte chemotactic responsiveness in humans with cancer, Clin. Res. 22:430A.Google Scholar
  61. Snyderman, R., Pike, M. C., Blaylock, B. L., and Weinstein, P., 1976, Effects of neoplasms on inflammation: Depression of macrophage accumulation after tumor implantation, J. Immunol. 116:585.PubMedGoogle Scholar
  62. Snyderman, R., Seigler, H. F., and Meadows, L., 1977, Abnormalities of monocyte to chemotaxis in patients with melanoma: Effects of immunotherapy and tumor removal, J. Natl. Cancer Inst. 58:37.PubMedGoogle Scholar
  63. Snyderman, R., Meadows, L., Holder, W., and Wells, S., Jr., 1978, Abnormal monocyte chemotaxis in patients with breast cancer: Evidence for a tumor-mediated effect, J. Natl. Cancer Inst. 60:737.PubMedGoogle Scholar
  64. Stevenson, M. M., and Meltzer, M. S., 1976, Depressed chemotactic responses in vitro of peritoneal macrophages from tumor-bearing mice, J. Natl. Cancer Inst. 57:847.PubMedGoogle Scholar
  65. Stevenson, M. M., Rees, J. C, and Meltzer, M. S., 1980, Macrophage function in tumor-bearing mice: evidence for lactic dehydrogenase-elevating virus-associated changes, J. Immunol. 124:2892.PubMedGoogle Scholar
  66. Stutman, O., 1975, Immunodepression and malignancy, Adv. Cancer Res. 22:261.PubMedCrossRefGoogle Scholar
  67. Till, G., and Ward, P. A., 1975, Two distinct chemotactic factor inactivators in human serum, J. Immunol. 114:843.PubMedGoogle Scholar
  68. Ward, P. A., and Berenberg, J. L., 1974, Defective regulation of inflammatory mediators in Hodg-kin’s disease. N. Engl. J. Med. 290:76.PubMedCrossRefGoogle Scholar
  69. Wood, B. W., and Gillespie, G. Y., 1975, Studies on the role of macrophages in regulation of growth and metastasis of murine chemically induced fibrosarcomas, Int. J. Cancer 16:1022.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • George J. Cianciolo
    • 1
  • Ralph Snyderman
    • 1
  1. 1.Laboratory of Immune Effector Function, Howard Hughes Medical Institute, Division of Rheumatic and Genetic Diseases, Department of MedicineDuke University Medical CenterDurhamUSA

Personalised recommendations